Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
2026 S3: prohibited at all times; Specified. A conditional inhaled exception applies; all limits and qualifications below matter. [1]
S3; printed p. 9 and relevant S5 note, p. 12 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and formulations
The checked UK Symbicort Turbohaler contains formoterol with budesonide. It has specified asthma and COPD uses, including particular clinician-directed asthma reliever regimens. Indications and regimens vary across products and countries. [2]
- Product and jurisdiction specific; this is not an exhaustive brand, indication or route inventory.
Selected health warnings
The product information distinguishes the metered amount inside the device from the delivered amount leaving the mouthpiece. It also warns about cardiovascular conditions, hypokalemia and paradoxical bronchospasm. A combination label must not be treated as instructions for formoterol alone. [2]
- No treatment dose, device conversion or personal eligibility determination is provided.
Limits of the inhaled exception
The 2026 inhaled exception is based on delivered formoterol: no more than 54 micrograms in 24 hours, in divided doses, and no more than 36 micrograms during any 12-hour interval starting with a dose. [1]
- These are anti-doping limits, not recommended or safe medical doses. Other routes, products, combined exposure and TUE requirements need individual review.
Urine findings and S5 interaction
The List’s urine threshold for formoterol is 40 ng/mL. Exceeding it leads to an adverse analytical finding unless the athlete establishes through a controlled pharmacokinetic study that it resulted from a therapeutic inhaled dose within the permitted maximum. A urine concentration is not an administered dose, and being below a threshold is not blanket permission. Under S5, detection of any quantity alongside a diuretic or masking agent is an adverse analytical finding unless there is an approved TUE for the threshold substance in addition to the diuretic or masking agent. That note excludes topical eye use of carbonic anhydrase inhibitors and local felypressin in dental anaesthesia. [1]
- Do not use these numbers to plan use or predict an individual test result. Refer to S3 and the complete S5 note.
What remains uncertain
- No exact ordinary-food or supplement-contamination pathway was established by the retained sources; this is a research limitation, not proof of absence.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- Symbicort Turbohaler 200 6 UK SmPC ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.